The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell

Anti-Cancer Drugs

Volumn 26, Issue 9, 2015, Pages 913-922

  Shi, Rui ^a   Lin, Juan ^a   Gong, Yuping ^a   Yan, Tianyou ^a   Shi, Fangfang ^a   Yang, Xi ^a   Liu, Xuehua ^a   Naren, Duolan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Acute lymphoblastic leukemia; Autophagy; Chronic myeloid leukemia; Imatinib; Metformin; Philadelphia chromosome; Resistance

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ADENYLATE KINASE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BLAST CELL; CANCER INHIBITION; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; LEUKEMIA CELL; LYMPHOBLAST; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; GENETICS; PATHOLOGY; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; AUTOPHAGY; BENZAMIDES; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MAP KINASE SIGNALING SYSTEM; METFORMIN; PHILADELPHIA CHROMOSOME; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; TUMOR CELLS, CULTURED;

EID: 84940950197     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000266     Document Type: Article

References (33)

1. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007; 109:3189-3197.
2. Liu-Dumlao T, Kantarjian H, Thomas DA, O'Brien S, Ravandi F. Philadelphiapositive acute lymphoblastic leukemia: current treatment options. Curr Oncol Rep 2012; 14:387-394.
3. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol 2012; 48:R31-R43.
4. Aljada A, Mousa SA. Metformin and neoplasia: implications and indications. Pharmacol Ther 2012; 133:108-115.
5. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and cancer risk in diabetic patients: a systematic review and metaanalysis. Cancer Prev Res (Phila) 2010; 3:1451-1461.
6. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE 2012; 7: e33411.
7. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010; 33:322-326.
8. Rizos CV, Elisaf MS. Metformin and cancer. Eur J Pharmacol 2013; 705:96-108.
9. Leone A, Di Gennaro E, Bruzzese F, Avallone A, Budillon A. New perspective for an old antidiabetic drug: metformin as anticancer agent. Cancer Treat Res 2014; 159:355-376.
10. Kim YH, Liang H, Liu X, Lee JS, Cho JY, Cheong JH, et al. AMPα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. Cancer Res 2012; 72:2512-2521.
11. Alayev A, Holz MK. mTOR signaling for biological control and cancer. J Cell Physiol 2013; 228:1658-1664.
12. Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A, et al. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis 2011; 2:e199.
13. Mizushima N. Autophagy: process and function. Genes Dev 2007; 21:2861-2873.
14. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011; 147:728-741.
15. Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green- Thompson ZW, et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev 2010; 90:1383-1435.
16. Morselli E, Galluzzi L, Kepp O, Vicencio JM, Criollo A, Maiuri MC, et al. Anti- and pro-tumor functions of autophagy. Biochim Biophys Acta 2009; 1793:1524-1532.
17. Kenific CM, Thorburn A, Debnath J. Autophagy and metastasis: another double-edged sword. Curr Opin Cell Biol 2010; 22:241-245.
18. White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 2009; 15:5308-5316.
19. Apel A, Zentgraf H, Büchler MW, Herr I. Autophagy-A double-edged sword in oncology. Int J Cancer 2009; 125:991-995.
20. Yang X, He G, Gong Y, Zheng B, Shi F, Shi R, Yang X. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph + acute lymphoblastic leukemia cells. Eur J Haematol 2014; 92:111-120.
21. Shi R, Lin J, Guo Y, Gong YP. The MEK1/2 inhibitor U0126 reverses imatinib resistance through down-regulating activation of Lyn/ERK signaling pathway in an imatinib-resistance K562R leukemia cells. Pharmazie 2014; 69:346-352.
22. Berenbaum MC. What is synergy? Pharmacol Rev 1989; 41:93-141.
23. Yang X, Lin J, Gong Y, Ma H, Shuai X, Zhou R, et al. Antileukaemia effect of rapamycin alone or in combination with daunorubicin on Ph + acute lymphoblastic leukaemia cell line. Hematol Oncol 2012; 30:123-130.
24. Ellington AA, Berhow MA, Singletary KW. Inhibition of Akt signaling and enhanced ERK1/2 activity are involved in induction of macroautophagy by triterpenoid B-group soyasaponins in colon cancer cells. Carcinogenesis 2006; 27:298-306.
25. Green AS, Chapuis N, Maciel TT, Willems L, Lambert M, Arnoult C, et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood 2010; 116:4262-4273.
26. Grimaldi C, Chiarini F, Tabellini G, Ricci F, Tazzari PL, Battistelli M, et al. AMP-dependent kinase/mammalian target of rapamycin complex1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia 2012; 26:91-100.
27. Guo Y, Shan Q, Gong Y, Lin J, Yang X, Zhou R. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph + acute lymphoblastic leukemia cells in vitro by down-regulating LYN/mTOR signaling pathway. Cancer Biol Ther 2012; 13:1244-1255.
28. Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERK-induced cell death-apoptosis, autophagy and senescence. FEBS J 2010; 277:2-21.
29. Deschênes-Simard X, Kottakis F, Meloche S, Ferbeyre G. ERKs in cancer: friends or foes? Cancer Res 2014; 74:412-419.
30. Trela E, Glowacki S, Błasiak J. Therapy of chronic myeloid leukemia: twilight of the imatinib era? ISRN Oncol 2014; 2014:596483.
31. Vakana E, Altman JK, Glaser H, Donato NJ, Platanias LC. Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood 2011; 118:6399-6402.
32. Shi WY, Xiao D, Wang L, Dong LH, Yan ZX, Shen ZX, et al. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis 2012; 3:e275.
33. Rosilio C, Ben-Sahra I, Bost F, Peyron JF. Metformin: a metabolic disruptor and anti-diabetic drug to target human leukemia. Cancer Lett 2014; 346:188-196.